Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Dec 7;13(1):21633.
doi: 10.1038/s41598-023-48839-2.

Efficacy of a computer based discontinuation strategy to reduce PPI prescriptions: a multicenter cluster-randomized controlled trial

Affiliations
Randomized Controlled Trial

Efficacy of a computer based discontinuation strategy to reduce PPI prescriptions: a multicenter cluster-randomized controlled trial

Julia Heisig et al. Sci Rep. .

Abstract

Deprescribing of inappropriate long-term proton pump inhibitors (PPI) is challenging and there is a lack of useful methods for general practitioners to tackle this. The objective of this randomized controlled trial was to evaluate the effectiveness of the electronic decision aid tool arriba-PPI on reduction of long-term PPI intake. Participants (64.5 ± 12.9 years; 54.4% women) with a PPI intake of at least 6 months were randomized to receive either consultation with arriba-PPI from their general practitioner (n = 1256) or treatment as usual (n = 1131). PPI prescriptions were monitored 6 months before, 6 and 12 months after study initiation. In 49.2% of the consultations with arriba-PPI, the general practitioners and their patients made the decision to reduce or discontinue PPI intake. At 6 months, there was a significant reduction by 22.3% (95% CI 18.55 to 25.98; p < 0.0001) of defined daily doses (DDD) of PPI. A reduction of 3.3% (95% CI - 7.18 to + 0.62) was observed in the control group. At 12 months, the reduction of DDD-PPI remained stable in intervention patients (+ 3.5%, 95% CI - 0.99 to + 8.03), whereas control patients showed a reduction of DDD-PPI (- 10.2%, 95% CI - 6.01 to - 14.33). Consultation with arriba-PPI led to reduced prescription rates of PPI in primary care practices. Arriba-PPI can be a helpful tool for general practitioners to start a conversation with their patients about risks of long-term PPI intake, reduction or deprescribing unnecessary PPI medication.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Flowchart of study participants.
Figure 2
Figure 2
Course of the adjusted means (adjusted at T1 and T2 by the ANCOVA models) of the DDD of PPI in the intervention and control groups (average DDD with standard errors).
Figure 3
Figure 3
PPI intake status and reason for intake as reported by the patients themselves at T1, stratified by the results of the arriba-PPI consultation at T0.

References

    1. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am. J. Gastroenterol. 2013;108:308–328. doi: 10.1038/ajg.2012.444. - DOI - PubMed
    1. Koop H, et al. S2k-Leitlinie. Gastroösophageale Refluxkrankkheit unter Federführung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS):AWMF Register Nr. 021-013. Zeitschrift fur Gastroenterologie. 2014;52:1299–1346. doi: 10.1055/s-0034-1385202. - DOI - PubMed
    1. Fischbach W, et al. S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit. Z. Gastroenterol. 2017;55:167–206. - PubMed
    1. Freedberg DE, Kim LS, Yang Y-X. The risks and benefits of long-term use of proton pump inhibitors. Expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152:706–715. doi: 10.1053/j.gastro.2017.01.031. - DOI - PubMed
    1. Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD: An overview of their pharmacology, efficacy and safety. Pharmacol. Res. 2009;59:135–153. doi: 10.1016/j.phrs.2008.09.016. - DOI - PubMed

Publication types

Substances